KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding
Others
Ratios

AbCellera Biologics (ABCL) EBT (2020 - 2023)

Historic EBT for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$48.6 million.

  • AbCellera Biologics' EBT fell 5472.43% to -$48.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$174.0 million, marking a year-over-year decrease of 17278.61%. This contributed to the annual value of -$200.4 million for FY2024, which is 1515.03% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' EBT is -$48.6 million, which was down 5472.43% from -$39.3 million recorded in Q3 2023.
  • Over the past 5 years, AbCellera Biologics' EBT peaked at $230.8 million during Q1 2022, and registered a low of -$48.6 million during Q4 2023.
  • In the last 4 years, AbCellera Biologics' EBT had a median value of -$2.4 million in 2020 and averaged $28.0 million.
  • The largest annual percentage gain for AbCellera Biologics' EBT in the last 5 years was 781557.57% (2021), contrasted with its biggest fall of 82729.3% (2021).
  • Quarter analysis of 4 years shows AbCellera Biologics' EBT stood at $161.2 million in 2020, then plummeted by 47.44% to $84.7 million in 2021, then plummeted by 137.08% to -$31.4 million in 2022, then plummeted by 54.72% to -$48.6 million in 2023.
  • Its last three reported values are -$48.6 million in Q4 2023, -$39.3 million for Q3 2023, and -$38.0 million during Q2 2023.